Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Consensus Price Target from Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average recommendation of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $9.40.

Several equities analysts have recently commented on the stock. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Bank of America dropped their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th.

Insider Buying and Selling

In related news, Director Blake Borgeson sold 220,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total value of $924,000.00. Following the completion of the transaction, the director directly owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This represents a 3.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Ben R. Taylor sold 13,426 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total value of $41,352.08. Following the completion of the sale, the chief financial officer owned 1,195,349 shares in the company, valued at approximately $3,681,674.92. This represents a 1.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 489,680 shares of company stock valued at $2,046,321 in the last three months. 8.43% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Hsbc Holdings PLC raised its stake in shares of Recursion Pharmaceuticals by 537.3% during the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after purchasing an additional 689,903 shares in the last quarter. Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $82,000. Corient Private Wealth LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $70,000. Invesco Ltd. grew its position in Recursion Pharmaceuticals by 25.8% in the 4th quarter. Invesco Ltd. now owns 526,144 shares of the company’s stock valued at $2,152,000 after buying an additional 107,979 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in Recursion Pharmaceuticals by 55.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 25,020 shares of the company’s stock valued at $100,000 after buying an additional 8,935 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $2.94 on Friday. Recursion Pharmaceuticals has a 12-month low of $2.91 and a 12-month high of $7.18. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -1.99 and a beta of 0.97. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01. The stock’s 50 day simple moving average is $3.74 and its 200 day simple moving average is $4.48.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million during the quarter, compared to the consensus estimate of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm’s revenue was up 671.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.53) EPS. Equities research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.